25 april 2026: Bron: Epub 2025 Mar 17.
Vitamine D suppletie met 2000 IU per dag verbetert het aantal complete remissies bij borstkankerpatiënten die neoadjuvante chemotherapie ondergaan in vergelijking met geen Vitamine D suppletie. Van de borstkankerpatiënten die naast chemo de Vitamine D suppletie kregen bereikte 43 procent een complete remissie. Van de vrouwen die alleen chemotherapie kregen en geen extra Vitamine D bereikte 24 procent een complete remissie.
Zo laat een kleinschalige maar wel geradomiseerde placebo gecontroleerde studie bij totaal 80 vrouwen zien.
Hier het abstract vrij vertaalt in het Nederlands:
- De vrouwen werden gerandomiseerd in twee groepen ingedeeld: een Vitamine D-groep, die gedurende 6 maanden dagelijks 2000 IE cholecalciferol (n = 40) kreeg, en een placebogroep (n = 40).
- De primaire uitkomstmaat was de bereikte complete remissies na de chemokuren.
- De serumspiegel van 25-hydroxyvitamine D [25(OH)D] werd gemeten na de diagnose borstkanker en na afloop van de vooraf gegeven chemokuren.
- Van de 80 deelnemende vrouwen voltooiden 75 de vooraf gegeven chemokuren en ondergingen daarna een operatie.
- De baseline 25(OH)D-waarden duidden op te lage bloedwaarden Vitamine D in beide groepen (Vitamine D groep: 19,6 ± 5,8 ng/ml en placebogroep: 21 ± 7,9 ng/ml, p = 0,33).
- Na 6 maanden waren de 25(OH)D-waarden in de Vitamine D groep gestegen ten opzichte van de placebogroep (28 ± 8,7 vs. 20,2 ± 6,1 ng/ml, p = 0,03).
- Het percentage pathologische complete remissies (pCR) was hoger bij vrouwen die Vitamine D kregen dan bij de placebogroep (43% vs. 24%, p = 0,04).
- Een aangepaste logistische regressieanalyse toonde aan dat vrouwen met 25(OH)D-waarden ≥ 20 ng/ml een grotere kans hadden op een complete remissie (OR 3,65, 95% CI 1,09-12,8, p = 0,04).
Conclusie:
Vrouwen met borstkanker die een neoadjuvante chemotherapie ondergingen en een supplement van 2000 IE vitamine D kregen, hadden een grotere kans op een pathologisch complete remissie dan vrouwen in de placebogroep.
Hier het abstract van deze studie. Het volledige studierapport is tegen betaling verkrijgbaar.
Randomized Controlled Trial
Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial
Affiliations
- PMID: 40098326
- DOI: 10.1080/01635581.2025.2480854
Abstract
This study aimed to evaluate the effect of vitamin D (VD) supplementation on the pathological complete response (pCR) rate in women with breast cancer (BC) undergoing neoadjuvant chemotherapy (NCT). A randomized clinical trial was conducted with 80 women aged ≥45years with BC who were eligible for NCT. Women were randomized into two groups: VD group, daily supplementation with 2,000IU of cholecalciferol (n = 40) or placebo (n = 40), for 6 months. The primary outcome measure was the pCR rate. Serum 25-hydroxyvitamin-D [25(OH)D] levels were measured after BC diagnosis and the end of NCT. Of the 80 randomized women, 75 completed the NCT and underwent surgery. Baseline 25(OH)D values indicated hypovitaminosis D in both groups (VD: 19.6 ± 5.8 ng/mL and placebo: 21 ± 7.9 ng/mL, p = 0.33). After 6 months, 25(OH)D levels increased in the VD group compared to the placebo group (28 ± 8.7 vs. 20.2 ± 6.1 ng/mL, p = 0.03). The pCR rate was higher in women supplemented with VD when compared than the placebo (43% vs. 24%, p = 0.04). Adjusted logistic regression showed that women with 25(OH)D levels ≥20ng/mL were more likely to achieve pCR (OR3.65, 95%CI 1.09-12.8, p = 0.04). Women with BC undergoing NCT who received supplementation with 2,000IU of VD were more likely to achieve a pathological complete response than women in the placebo group.
Trial registration: Ensaiosclinicos.gov.br, identifier RBR-10k4gqdg.
Similar articles
-
Vitamin D supplementation improves the metabolic syndrome risk profile in postmenopausal women.Climacteric. 2020 Feb;23(1):24-31. doi: 10.1080/13697137.2019.1611761. Epub 2019 May 28.PMID: 31134822Clinical Trial.
-
A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy.Nutrients. 2021 Dec 10;13(12):4429. doi: 10.3390/nu13124429.PMID: 34959982Free PMC article.Clinical Trial.
-
Effect of Antenatal Oral Vitamin D Supplementation on Serum 25(OH)D Concentration in Exclusively Breastfed Infants at 6 Months of age - A Randomized Double-Blind Placebo-Controlled Trial.Indian Pediatr. 2024 Jun 15;61(6):533-539. Epub 2024 Apr 5.PMID: 38584410Clinical Trial.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.Update in:Cochrane Database Syst Rev. 2026 Feb 18;2:CD014217. doi: 10.1002/14651858.CD014217.pub2.PMID: 36321557Free PMC article.
-
Vitamin D supplementation for sickle cell disease.Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD010858. doi: 10.1002/14651858.CD010858.pub2.Update in:Cochrane Database Syst Rev. 2020 May 28;5:CD010858. doi: 10.1002/14651858.CD010858.pub3.PMID: 28105733Free PMC article.
Cited by
-
The association of serum vitamin D3 and vitamin D binding protein levels before and after treatment with the response to neoadjuvant chemotherapy in Egyptian breast cancer patients: a prospective observational study.Naunyn Schmiedebergs Arch Pharmacol. 2026 Mar;399(6):8089-8099. doi: 10.1007/s00210-025-04644-4. Epub 2025 Dec 20.PMID: 41420735Free PMC article.
-
Beyond the Limit: MYC Mediates Tumor Immune Escape.Pharmaceuticals (Basel). 2025 Jun 29;18(7):978. doi: 10.3390/ph18070978.PMID: 40732268Free PMC article.Review.
-
Impact of vitamin D deficiency and inflammatory biomarkers on pathological response to neoadjuvant chemotherapy in breast cancer.Clin Transl Oncol. 2026 Jan 12. doi: 10.1007/s12094-025-04194-4. Online ahead of print.PMID: 41525036
-
Modeling CAF-tumor interactions to overcome therapy resistance.J Exp Clin Cancer Res. 2026 Jan 8;45(1):41. doi: 10.1186/s13046-025-03633-y.PMID: 41501921Free PMC article.Review.
-
Relationship of vitamin D receptor expression with hormone receptors and other clinicopathological features in primary breast carcinomas: A retrospective cross-sectional study.Medicine (Baltimore). 2025 Aug 29;104(35):e44222. doi: 10.1097/MD.0000000000044222.PMID: 40898467Free PMC article.
References
- Carlberg C, Velleuer E. Vitamin D and the risk for cancer: a molecular analysis. Biochem Pharmacol. 2022;196:114735. doi:10.1016/j.bcp.2021.114735.
- Welsh J. Vitamin D and breast cancer: past and present. J Steroid Biochem Mol Biol. 2018;177:15–20. doi:10.1016/j.jsbmb.2017.07.025.
- Hossain S, Beydoun MA, Beydoun HA, Hen X, Zonderman AB, Wood RJ. Vitamin D and breast cancer: a systematic review and meta-analysis of observational studies. Clin Nutr ESPEN. 2019;30:170–84. doi:10.1016/j.clnesp.2018.12.085.
- Chartron E, Firmin N, Touraine C, Chapelle A, Legouffe E, Rifai L, Pouderoux S, Roca L, D’Hondt V, Jacot W. A Phase II multicenter trial on high-dose vitamin D supplementation for the correction of vitamin D insufficiency in patients with breast cancer receiving adjuvant chemotherapy. Nutrients. 2021;13(12):4429. doi:10.3390/nu13124429.
- Shirvani A, Kalajian TA, Song A, Holick MF. Disassociation of vitamin D’s calcemic activity and non-calcemic genomic activity and individual responsiveness: a randomized controlled double-blind clinical trial. Sci Rep. 2019;9(1):17685. doi:10.1038/s41598-019-53864-1.
- Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342–57. doi:10.1038/nrc3691.
- Tretli S, Schwartz GG, Torjesen PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control. 2012;23(2):363–70. doi:10.1007/s10552-011-9885-6.
- Muñoz A, Grant WB. An historical overview of the epidemiology and mechanisms. Nutrients. 2022;14(7):1448. doi:10.3390/nu14071448.
- Pandolfi F, Franza L, Mandolini C, Conti P. Immune modulation by vitamin D: special emphasis on its role in prevention and treatment of cancer. Clin Ther. 2017;39(5):884–93. doi:10.1016/j.clinthera.2017.03.012.
- Sheng L, Callen DF, Turner AG. Vitamin D 3 signaling and breast cancer: insights from transgenic mouse models. J Steroid Biochem Mol Biol. 2018;178:348–53. doi:10.1016/j.jsbmb.2018.02.006.
- Carlberg C, Muñoz A. An update on vitamin D signaling and cancer. Semin Cancer Biol. 2022;79:217–30. doi:10.1016/j.semcancer.2020.05.018.
- Mohr SB, Gorham ED, Kim J, Hofflich H, Garland CF. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer Res. 2014;34(3):1163–6.
- Almeida-Filho BS, Omodei MS, Buttros D, Carvalho-Pessoa E, Carvalho-Pessoa CP, Vespoli H, Nahas EAP. Negative impact of vitamin D deficiency at diagnosis on breast cancer survival: a prospective cohort study. Br Journal. 2022;2022:1–9. doi:10.1155/2022/4625233.
- Machado M, Almeida-Filho BS, Vespoli HL, Schmitt EB, Nahas-Neto J, Nahas EAP. Low pretreatment serum concentration of vitamin D at breast cancer diagnosis in postmenopausal women. Menopause. 2019;26(3):293–9. doi:10.1097/GME.0000000000001203.
- Voutsadakis IA. Vitamin D baseline levels at diagnosis of breast cancer: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021;14(1):16–26. doi:10.1016/j.hemonc.2020.08.005.
- Sousa Almeida-Filho B, De Luca Vespoli H, Pessoa EC, Machado M, Nahas-Neto J, Nahas EAP. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women. J Steroid Biochem Mol Biol. 2017;174:284–9. doi:10.1016/j.jsbmb.2017.10.009.
- Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer ASCO guideline. J Clin Oncol. 2021;39(13):1485–505. doi:10.1200/JCO.20.03399.
- Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. doi:10.1016/S0140-6736(13)62422-8.
- Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A, I-SPY1 Investigators. Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657). Cancer Med. 2014;3(3):693–701. doi:10.1002/cam4.235.
- Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, Dutch Breast Cancer Research Group (BOOG), et al. Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: data from the NEOZOTAC trial (BOOG 10-01). Breast. 2016;25:69–74. doi:10.1016/j.breast.2015.10.005.
- Kim JS, Haule CC, Kim JH, Lim SM, Yoon KH, Kim JY, Park HS, Park S, Kim SI, Cho YU, et al. Association between changes in serum 25-hydroxyvitamin D levels and survival in patients with breast cancer receiving neoadjuvant chemotherapy. J Breast Cancer. 2018;21(2):134–41. doi:10.4048/jbc.2018.21.2.134.
- Tokunaga E, Masuda T, Ijichi H, Tajiri W, Koga C, Koi Y, Nakamura Y, Ohno S, Taguchi K, Okamoto M. Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer. 2022;29(1):156–63. doi:10.1007/s12282-021-01292-3.
- Chiba A, Raman R, Thomas A, Lamy PJ, Viala M, Pouderoux S, Mott SL, Schroeder MC, Thezenas S, Jacot W. Serum vitamin D levels affect pathologic complete response in patients undergoing neoadjuvant systemic therapy for operable breast cancer. Clin Breast Cancer. 2018;18(2):144–9. doi:10.1016/j.clbc.2017.12.001.
- Viala M, Chiba A, Thezenas S, Delmond L, Lamy PJ, Mott SL, Schroeder MC, Thomas A, Jacot W. Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. BMC Cancer. 2018;18(1):770. doi:10.1186/s12885-018-4686-x.
- Ozmen MDV, Ordu MDC, Ilgun MDAS, Unal MDC, Soybir MDG, Erdogan MDZ, Tapan MSTK, Aktepe MDF, Alco MDG, Duymaz MST, et al. T. The effects of vitamin D replacement on pathological complete response (pCR) in breast cancer patients receiving neoadjuvant systemic chemotherapy (NAC). Breast J. 2021;27(12):902–5. doi:10.1111/tbj.14299.
- Alamoodi M. Factors affecting pathological complete response in locally advanced breast cancer cases receiving neoadjuvant therapy: a comprehensive literature review. Eur J Breast Health. 2024;20(1):8–14. doi:10.4274/ejbh.galenos.2023.2023-11-2.
- Madden JM, Murphy L, Zgaga L, Bennett K. De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival. Breast Cancer Res Treat. 2018;172(1):179–90. doi:10.1007/s10549-018-4896-6.
- Vaughan-Shaw PG, O’Sullivan F, Farrington SM, Theodoratou E, Campbell H, Dunlop MG, Zgaga L. The impact of vitamin D pathway genetic variation and circulating 25- hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. Br J Cancer. 2017;116(8):1092–110. doi:10.1038/bjc.2017.44.
- Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 8th ed. New York (NY): Springer International Publishing: American Joint Commission on Cancer; 2017.
- Szymiczek A, Lone A, Akbari MR. Molecular intrinsic versus clinical subtyping in breast cancer: a comprehensive review. Clin Genet. 2021;99(5):613–37. doi:10.1111/cge.13900.
- Gospodarska E, Ghosh Dastidar R, Carlberg C. Intervention approaches in studying the response to vitamin D3 supplementation. Nutrients. 2023;15(15):3382. doi:10.3390/nu15153382.
- Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine S, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30. doi:10.1210/jc.2011-0385.
- Elston EW, Ellis IO. Method for grading breast cancer. J Clin Pathol. 1993;46(2):189–90. doi:10.1136/jcp.46.2.189-b.
- Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907–22. doi:10.5858/134.6.907.
- Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centers. J Pathol. 2003;199(4):418–23. doi:10.1002/path.1313.
- Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Strategies for subtypes– dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2011. Ann Oncol. 2011;22(8):1736–47. doi:10.1093/annonc/mdr304.
- The College of American Pathologists. The CAP cancer protocols. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates(open in a new window).
- Verstuyf A, Carmeliet G, Bouillon R, Mathieu C. Vitamin D: a pleiotropic hormone. Kidney Int. 2010;78(2):140–5. doi:10.1038/ki.2010.17.
- Krishnan AV, Swami S, Feldman D. The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids. 2012;77(11):1107–12. doi:10.1016/j.steroids.2012.06.005.
- Huss L, Butt ST, Borgquist S, Elebro K, Sandsveden M, Rosendahl A, Manjer J. Vitamin D receptor expression in invasive breast tumors and breast cancer survival. Breast Cancer Res. 2019;21(1):84. doi:10.1186/s13058-019-1169-1.
- Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J. 2012;441(1):61–76. doi:10.1042/BJ20110744.
- Augustin LS, Libra M, Crispo A, Grimaldi M, De Laurentiis M, Rinaldo M, D’Aiuto M, Catalano F, Banna G, Ferrau F, et al. Low glycemic index diet, exercise and vitamin D to reduce breast cancer: design of a clinical trial. BMC Cancer. 2017;17(1):69. doi:10.1186/s12885-017-3064-4.
- Chaudhry M, Sundaram S, Gennings C, Carter H, Gewirtz DA. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol. 2001;47(5):429–36. doi:10.1007/s002800000251.
- Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. 2001;7(4):1043–51.
- Sundaram S, Chaudhry M, Reardon D, Gupta M, Gewirtz DA. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of Adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat. 2000;63(1):1–10. doi:10.1023/a:1006420708806.
- Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res. 2000;60(7):2040–8.
- Jacot W, Pouderoux S, Thezenas S, Chapelle A, Bleuse JP, Romieu G, Lamy PJ. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2012;134(2):709–17. doi:10.1007/s10549-012-2084-7.
- Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer. 2002;97(1):129–32. doi:10.1002/ijc.1568.
- Akay BN, Unlu E, Buyukcelik A, Akyol A. Photosensitive rash in association with porphyrin biosynthesis possibly induced by docetaxel and trastuzumab therapy in a patient with metastatic breast carcinoma. Jpn J Clin Oncol. 2010;40(10):989–91. doi:10.1093/jjco/hyq085.
- Naito Y, Kai Y, Ishikawa T, Fujita T, Uehara K, Doihara K, Tokunaga S, Shimokawa M, Ito Y, Saeki T. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer. 2020;27(1):122–8. doi:10.1007/s12282-019-01001-1.
- Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D’Agostino D, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44. doi:10.1056/NEJMoa1809944.
- Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009;19(7):468–83. doi:10.1016/j.annepidem.2009.03.021.
- Giustina A, Bilezikian JP, Adler RA, Banfi G, Bikle DD, Binkley NC, Bollerslev J, Bouillon R, Brandi ML, Casanueva FF, et al. Consensus statement on vitamin D status assessment and supplementation: whys, whens, and hows. Endocr Rev. 2024;45(5):625–54. doi:10.1210/endrev/bnae009.
Gerelateerde artikelen
- Vitamine D suppletie geeft meer complete remissies bij borstkankerpatiënten die vooraf aan operatie chemotherapie ondergaan in vergelijking met geen vitamine D suppletie
- Vitamine C intraveneus gegeven vermindert bij vrouwen onder behandeling van borstkanker misselijkheid, vermoeidheid, eetlustverlies en pijn.
- Hoge vitamine D (25-hydroxyvitamin D) waarden in bloed geven significant minder risico - 44 procent - op overlijden aan borstkanker dan bij lage vitamine D. waarden op moment van diagnose
- Antioxidanten en extra vitamines zoals vitamine C en E vergroten significant de kansen op overleven en geeft significant minder recidieven voor borstkankerpatienten met invasieve borstkanker. Ook naast chemo blijft positieve effect hetzelfde
- Betaglucaan stimuleert monocyten (immuunstimulering) in bloed van borstkankerpatienten blijkt uit een kleine studie met 23 borstkankerpatiënten.
- Vrouwen welke eerder behandeld zijn voor borstkanker en die daarna veel fruit en groenten gaan gebruiken hebben significant minder risico op het krijgen van een recidief of duurt significant langere tijd voor een recidief optreedt
- Multivitamines met mineralen - MVM - vermindert kans op overlijden met 30 procent voor oudere vrouwen met borstkanker copy 1
- Q-10 en vitamines B2 en B3 ((ribofalvin en niacin) verlagen significant CEA en CA 15-3 markers als aanvulling op Tamoxifen en zorgt voor beduidend kleinere kans op recidief.
- Vitamine D spiegel blijkt goede voorspeller van kansen op langer leven van postmenopauzale vrouwen met borstkanker stadium II en III bij standaard behandeling plus Zometa - zoledronic acid.
- Vitamine D (uit zonlicht, vis of tabletje) versterkt botdichtheid (BMD) en verbetert daarmee beduidend de werking van bisfosfonaten bij postmenopausale vrouwen en vitamine D. versterkt botdichtheid bij meisjes en jonge vrouwen
- Vitamine D. heeft gunstig effect en geeft beduidend minder risico op krijgen van borstkanker en eierstokkanker blijkt uit verschillende studies gepresenteerd op ASCO 2006..
- Vitamine D plus calcium vermindert significant pijn veroorzaakt door aromaseremmers zoals Arimidex bij borstkankerpatienten blijkt uit gerandomiseerde placebo gecontroleerde fase II studie
- Vitamine D. heeft gunstig effect en geeft beduidend minder risico op krijgen van borstkanker en eierstokkanker blijkt uit verschillende studies gepresenteerd op ASCO 2006.
- Vitamine D tekort gerelateerd aan agressievere vormen van borstkanker en aan slechtere prognose
- Antioxidanten, mineralen en vitamines als aanvulling bij borstkanker: een overzicht
Plaats een reactie ...
Reageer op "Vitamine D suppletie geeft meer complete remissies bij borstkankerpatiënten die vooraf aan operatie chemotherapie ondergaan in vergelijking met geen vitamine D suppletie"